This week, Jeremy is joined by Larry Falivena, a member of The ALS Association’s Board of Trustees and Dr. Kuldip Dave, vice president of research at The ALS Association, for reaction to the decision by an FDA advisory committee to clear the path for approval of tofersen – and why it’s important for the future of the drug development pipeline.

Read more about why the tofersen decision is important for everyone at https://www.als.org/blog/heres-why-fda-committees-recommendation-tofersen-matters-everyone

Read more on the potential role neurofilament light can play in drug development at https://www.biopharmadive.com/news/neurofilament-als-drug-development-fda-biomarker/646048/ 

Listen to our conversation with Dr. Michael Benatar about his research on using gene therapies to prevent ALS at https://share.transistor.fm/s/1ac18819

This episode is brought to you by The ALS Association in partnership with CitizenRacecar.